Stay updated with breaking news from Retinal disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Electroretinography Market Poised for Remarkable Growth, to Surpass USD 109.7 Million by 2033, Enabl pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Prevent Blindness Ohio declares May as first-ever Inherited Retinal Disease Genetic Testing Awareness Month highlandcountypress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from highlandcountypress.com Daily Mail and Mail on Sunday newspapers.
Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME. ....
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on October 27, 2023, from Atlas Special Opportuni ....
EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”). On Septe ....